Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALEC logo ALEC
Upturn stock ratingUpturn stock rating
ALEC logo

Alector Inc (ALEC)

Upturn stock ratingUpturn stock rating
$1.4
Last Close (24-hour delay)
Profit since last BUY-1.41%
upturn advisory
WEAK BUY
BUY since 23 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ALEC (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $4.65

1 Year Target Price $4.65

Analysts Price Target For last 52 week
$4.65Target price
Low$0.87
Current$1.4
high$6.78

Analysis of Past Performance

Type Stock
Historic Profit -64.24%
Avg. Invested days 18
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 147.99M USD
Price to earnings Ratio -
1Y Target Price 4.65
Price to earnings Ratio -
1Y Target Price 4.65
Volume (30-day avg) 9
Beta 0.72
52 Weeks Range 0.87 - 6.78
Updated Date 06/30/2025
52 Weeks Range 0.87 - 6.78
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.26

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -139.74%
Operating Margin (TTM) -1216.52%

Management Effectiveness

Return on Assets (TTM) -17.22%
Return on Equity (TTM) -90.26%

Valuation

Trailing PE -
Forward PE 526.32
Enterprise Value -165513952
Price to Sales(TTM) 1.68
Enterprise Value -165513952
Price to Sales(TTM) 1.68
Enterprise Value to Revenue 2.38
Enterprise Value to EBITDA -8.4
Shares Outstanding 99992600
Shares Floating 73907530
Shares Outstanding 99992600
Shares Floating 73907530
Percent Insiders 9.95
Percent Institutions 80.82

Analyst Ratings

Rating 3
Target Price 4.65
Buy 1
Strong Buy 5
Buy 1
Strong Buy 5
Hold 1
Sell 1
Strong Sell 1
Strong Sell 1

ai summary icon Upturn AI SWOT

Alector Inc

stock logo

Company Overview

overview logo History and Background

Alector Inc. was founded in 2013. It is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Alector's focus is on harnessing the power of the immune system to combat diseases like Alzheimer's and frontotemporal dementia (FTD).

business area logo Core Business Areas

  • Immuno-Neurology Drug Development: Alector focuses on discovering and developing therapies that target immune cell dysfunction in the brain to treat neurodegenerative diseases.

leadership logo Leadership and Structure

Alector Inc. has a management team led by a Chief Executive Officer (CEO) and other key executives overseeing various departments, including research and development, clinical operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • AL001 (titration of a monoclonal antibody targeting Signal Regulatory Protein alpha (SIRPu03b1)): AL001 targets CD47 to treat frontotemporal dementia (FTD). In 2017, Alector entered into a global co-development and co-commercialization partnership with AbbVie, now Allergan, for AL001. There is no precise market share available, but it is in clinical trials and represents a significant opportunity. Competitors include companies targeting the same disease area with different therapeutic approaches, e.g., gene therapy or other antibody approaches for FTD. Allergan is a partner.
  • AL101 (progranulin agonist): AL101 is a progranulin (PGRN) agonist also targeting FTD. There is no precise market share data publicly available. Competitors include those focusing on FTD treatments and other immuno-neurology companies. No partner is currently associated to this drug.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry, specifically targeting neurodegenerative diseases, is characterized by high unmet needs, significant research and development investment, and regulatory hurdles. The Alzheimer's and dementia market are expected to grow significantly due to the aging population.

Positioning

Alector is positioned as a leader in the emerging field of immuno-neurology, aiming to address neurodegenerative diseases by modulating the immune system. Its competitive advantage lies in its novel approach.

Total Addressable Market (TAM)

The TAM for neurodegenerative diseases is estimated to be in the tens of billions of dollars, with Alzheimer's disease alone representing a significant portion. Alector, if successful with its pipeline, is positioned to capture a portion of this market.

Upturn SWOT Analysis

Strengths

  • Novel immuno-neurology approach
  • Strong pipeline of drug candidates
  • Partnership with established pharmaceutical companies (e.g. Allergan)
  • Experienced management team

Weaknesses

  • High risk associated with clinical-stage drug development
  • Dependence on clinical trial outcomes
  • Limited revenue stream currently
  • Reliance on partnerships for funding

Opportunities

  • Expanding pipeline into other neurodegenerative diseases
  • Potential for breakthrough therapies in areas with high unmet need
  • Strategic collaborations with other biotech and pharmaceutical companies
  • Advancements in diagnostics for neurodegenerative diseases to improve patient selection

Threats

  • Clinical trial failures
  • Regulatory hurdles and delays
  • Competition from other companies developing therapies for neurodegenerative diseases
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • Biogen Inc. (BIIB)
  • Eli Lilly and Company (LLY)
  • Roche Holding AG (RHHBY)

Competitive Landscape

Alector faces competition from established pharmaceutical companies with broader portfolios and greater resources. Its advantage lies in its specialized focus on immuno-neurology.

Growth Trajectory and Initiatives

Historical Growth: Alector's growth is primarily driven by its clinical pipeline and partnerships.

Future Projections: Future growth depends on clinical trial success and potential FDA approval of its drug candidates. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include advancing its lead drug candidates through clinical trials and exploring new immuno-neurology targets.

Summary

Alector is a clinical-stage biotech company pioneering immuno-neurology. Its novel approach targeting the immune system to combat neurodegenerative diseases is promising. Clinical trial success is critical to its growth. It must manage competition and regulatory hurdles effectively.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports

Disclaimers:

The data provided is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may not be precise. Financial data should be verified independently.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Alector Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2019-02-07
Co-Founder, CEO & Director Dr. Arnon Rosenthal Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 175
Full time employees 175

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.